Monthly Archives: July 2018

Detecting autism spectrum disorders: biomarker discoveries

feature image – square

A biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic intervention.” Biomarkers decrease our reliance on subjective patient, caregiver, or clinician ratings and are especially important for individuals who are unable to describe their physical or mental states.

Evolution, religion, and why it’s not just about lack of scientific reasoning ability

michelangelo-71282_640

Despite overwhelming evidence for evolution, many people still choose to reject it as an explanation for how humans and other organisms evolved and developed. This attitude seems to be especially common amongst religious people. But why is that, and what can we do to reconcile these two opposing worldviews? A new study published in Evolution: Education and Outreach tries to explain.

13

Cannabis use in psychiatric populations and risk of suicide: A new perspective

In the first study of its kind, a team of researchers in Canada examined marijuana (cannabis) use and the risk of suicidal behavior in psychiatric populations rather than the general population to see if similar results would be found (i.e., marijuana use increases suicidal behaviors). What they found could be used to inform the medical community working with these psychiatric populations in their assessment of suicide risk.

Bioelectronic Medicine: Technology Targeting Molecular Mechanisms

IMG_6904

In this blog Margot Puerta reports on the Bioelectronic Medicine: Technology Targeting Molecular Mechanisms symposium which took place in June. This three-day meeting had the aim of developing the field of bioelectronic medicine and brought together leading scientists and industry leaders from around the globe.

Efficient but unpredictable CRISPR

Blog picture for BMC

Continued technical developments in genome engineering have recently allowed the generation of conditional mouse models using long DNA templates. Lydia Teboul, author of a new study in BMC Biology, explains how these long templates can also be used to create point mutations away from the target site, but additional unwanted modifications render the validation of new mutants essential.

33rd International conference Alzheimer’s Disease International 2018

FB-1200-x-630

On July 26th – July 29th the 33rd international conference of Alzheimer’s Disease International (ADI) will be descending on Chicago. This blog gives you a flavor of the interesting research and information that you will be able to find at the conference. BMC will be attending the conference so please find come and find us to hear more about the exciting work we are undertaking.

Assessing cognition in patients with early Alzheimer’s disease – an experts views on the new FDA guidance

dementia-3051832_960_720

A recent commentary published in Alzheimer’s Research and Therapy highlights the benefits and flaws of the new FDA guidelines for Alzheimer’s drug development. In this blog John Harrison, an associate professor at the Alzheimer Center at the VU Medical Center in Amsterdam, sheds some light on the new FDA guidelines and what this means for the future of Alzheimer’s drug development.